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ABSTRACT
OBJECTIVE: To evaluate the effectiveness of antiretroviral therapy and the associated factors 
according to the type of regimen used: Single Tablet Regimen or Multiple Tablet Regimen. 
METHODS: Prospective cohort of 440 patients (male, 74.3%, median age, 36 years old) who 
initiated antiretroviral therapy between Jan/14 and Dec/15 at a referral service in Belo Horizonte. 
Efficacy was defined as viral suppression (viral load, VL < 50 copies/ml) and evaluated after six 
and twelve months of treatment. Sociodemographic, clinical and behavioral data were collected 
from clinical charts and from Information Systems. Multivariate analysis of overall effectiveness 
was performed by logistic regression. 
RESULTS: Most patients initiated Multiple Tablet Regimen antiretroviral therapy (n = 255, 58%). 
At six months, overall viral suppression was 74.6%, being higher among patients who used Single 
Tablet Regimen (80.6%, p = 0.04). At twelve months, 83.2% of patients reached viral suppression, 
with no difference between groups (p = 0.93). Factors independently associated with viral 
suppression at six and twelve months varied, being negatively associated with effectiveness: VL 
≥ 100,000 copies/ml, symptoms of AIDS, longer interval time between diagnosis and initiation of 
antiretroviral therapy, antiretroviral switching, smoking or current illicit drugs usage (p < 0.05). 
Factors positively associated with viral suppression included adherence to antiretroviral therapy 
and category of risk/exposure of men who have sex with men (p < 0.05). Reaching viral suppression 
at six months was the main predictor of effectiveness at one year (OR = 8.96 and p < 0.01). 
CONCLUSIONS: Viral suppression was high and better results were achieved for patients who 
used Single Tablet Regimen regimens at six months. Clinical, behavioral, and antiretroviral 
therapy -related factors influence viral suppression and highlight the need for interventions 
to increase early diagnosis and initiation of antiretroviral therapy, patient’s adherence, and to 
reduce illicit drugs and cigarette smoking in this population.
DESCRIPTORS: Anti-HIV Agents, administration & dosage. Antiretroviral Therapy, Highly 
Active. Evaluation of the Efficacy-Effectiveness of Interventions. Cohort Studies. 
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INTRODUCTION
An estimated 830,000 people were living with HIV in Brazil by the end of 2016, a prevalence 
of 0.4% in the general population. This prevalence is higher among sex workers, injecting 
drug users, men who have sex with men (MSM), and persons deprived of libertya,b. Of this 
total, about 498 thousand people use antiretroviral therapy (ART), a coverage rate of 60%b.
Since 1996, the Brazilian Unified Health System (SUS) has offered ART as part of its care 
policy for people living with HIV (PLHIV)1. Currently, 22 antiretroviral drugs (ARV) are 
provided for HIV control, including the single-tablet regimen (STR) of tenofovir, lamivudine 
and efavirenz, listed in 2015c.
The STR have allowed the simplification of ART and the administration of a single 
tablet per day compared to multiple-tablet regimens (MTR). The benefits include greater 
patient preference, increased self-perceived health, greater adherence to ART, greater 
viral suppression, better laboratory parameters and reduction of associated costs2. Thus, 
several clinical protocols, in agreement with the recommendations of the World Health 
Organization, favor the use STR as initial therapy2,d.
The Brazilian Ministry of Health invested over R$ 1 billion in antiretroviral drugs and the 
treatment of sexually transmitted diseases in 2016e. Despite the high investment, studies 
on the effectiveness of these drugs in Brazil are scarce. Recently published studies3,4 
are restricted to patients who initiated ART by 2010, when STR were not available and 
recommendations for initial ART depended on CD4 + T lymphocytes (CD4 + TL) and viral 
load (VL) levels of patients, as opposed to the current recommendation to initiate treatment 
promptly, regardless of such parametersc. Added to that is the lack of observational studies 
in ART-naïve patients who used specifically the STR containing tenofovir, lamivudine 
and efavirenz.
We aimed to evaluate the effectiveness of antiretroviral drugs in PLHIV according to the 
type of regimen (STR or MTR) used in the treatment and associated factors.
METHODS
A non-concurrent prospective cohort of patients who initiated ART between January 
2014 and December 2015 at an HIV specialized service (SAE) that provides inpatient and 
outpatient care in Belo Horizonte, the major point of reference in Minas Gerais.
A total of 1,249 patients were identified in Sistema de Controle Logístico de Medicamentos 
(Siclom – Logistic Control System of Medicines) and in HIV and AIDS reports issued by 
the SAE. Of those, 440 met the inclusion criteria (Figure). The following were considered 
eligible: patients aged 16 or over, diagnosed with HIV, ART-naïve and with at least one 
outpatient healthcare visit after initiating ART. Pregnant women were excluded due to 
different therapy indications. 
The data were collected from medical records, Siclom and Sistema de Controle de Exames 
Laboratoriais da Rede Nacional de Contagem de Linfócitos CD4+/CD8+ e Carga Viral (Siscel 
– Laboratory Examination Control System) The data collected in medical records were: 
sociodemographic (sex, race, age, marital status, level of education, children, employment); 
behavioral and lifestyle habits (use of tobacco, alcohol and illicit drugs, prior and during 
follow-up); clinical/laboratory [possible sources of infection, hospitalizations in the previous 
year and after initiating ART, initial clinical classification of patient (according to adapted 
criteria of the Centers for Disease Control and Preventionf) and diagnoses of comorbidities 
and coinfections (according to criteria of the International Classification of Diseases, tenth 
revisiong)]; and drug therapy (time between diagnosis and initial ART; therapy regimen used; 
record of adverse events; and adherence, characterized by the absence of non-adherence notes 
in the medical record).
a Boletim Epidemiológico de 
Aids e DST. Brasília (DF): 
Ministério da Saúde, Secretaria 
de Vigilância em Saúde; 2016 
[cited 2017 Mar 3];5(1). 
Available from: http://www.aids.
gov.br/pt-br/pub/2016/boletim-
epidemiologico-de-aids-2016
b Ministério da Saúde (BR), 
Secretaria de Vigilância em 
Saúde, Departamento de 
Vigilância, Prevenção e Controle 
das Infecções Sexualmente 
Transmissíveis, do HIV/AIDS e 
das Hepatites Virais. Relatório de 
monitoramento clínico do HIV. 
Brasília (DF); 2017. Available 
from: http://www.aids.gov.br/
pt-br/pub/2017/relatorio-de-
monitoramento-clinico-do-hiv
c Ministério da Saúde (BR), 
Secretaria de Vigilância em 
Saúde, Departamento de 
Vigilância, Prevenção e Controle 
das Infecções Sexualmente 
Transmissíveis, do HIV/AIDS e das 
Hepatites Virais. Protocolo clínico 
e diretrizes terapêuticas para 
manejo da infecção pelo HIV em 
adultos. Brasília (DF); 2013. 
d World Health Organization. 
Consolidated guidelines on the use 
of antiretroviral drugs for treating 
and preventing HIV infection: 
recommendations for a public 
health approach. 2.ed. Geneva: 
WHO; 2016 [cited 2017 Apr 20]. 
Available from: http://www.who.
int/hiv/pub/arv/arv-2016/en/
e Ministério da Transparência e 
Controladoria-Geral da União 
(BR). Portal da Transparência: 
gastos diretos do Governo 
por ação: exercício de 2016. 
Brasília (DF); 2017 [cited 2017 
Mar 3]. Available from: http://
www.transparencia.gov.br/
PortalComprasDiretas
f Ministério da Saúde (BR), 
Secretaria de Vigilância em Saúde, 
Programa Nacional de DST e Aids. 
Critérios de definição de casos 
de AIDS em adultos e crianças. 
Brasília (DF); 2004 [cited 2017 Apr 
20]. Available from: http://bvsms.
saude.gov.br/bvs/publicacoes/
criterios_definicao_AIDS_adultos_
criancas.pdf
g World Health Organization. 
ICD-10: international statistical 
classification of diseases and 
related health problems: tenth 
revision. 2.ed. Geneva: WHO; 
2004 [cited 2017 Apr 20]. 
Available from: http://apps.who.
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The ARV switch was collected from Siclom and defined as replacement of an initially 
prescribed active ingredient. The results of the CD4 + TL and VL counts performed during 
follow-up were collected from Siscel or, when unavailable, from the patient’s medical record.
Data collection was carried out by two trained researchers using a standardized form and 
typed in EpiInfo 3.5.4 software. Collection and typing quality was verified by recollecting 
and retyping 10% of medical records with Kappa statistic value, indicating perfect inter-
examiner agreement (k = 0.92)5.
Patient follow-up lasted 12 months. The initial date of therapy was determined by the first 
dispensation of ART to outpatients registered with Siclom or the first dispensation of ART 
registered in the medical record of patients who began therapy during hospitalization.
Therapy effectiveness was defined as viral suppression (plasma VL < 50 copies/ml) six 
months after initial treatmentc. Immunological effectiveness and recovery were evaluated 
as secondary outcomes (increase of more than 30% of CD4 + levelsc) after 12 months of 
follow-up. A three-month tolerance was used to collect test results to reduce the amount 
of missing data.
Patients were compared according to initial therapy regimen: STR or MTR. Categorical 
variables were presented by frequency distribution and quantitative variables by central 
tendency (mean or median) and variability (SD: standard deviation and TA: total amplitude). 
The chi-square test was used to compare the groups.
The magnitude of the association between the explanatory variables and effectiveness 
was estimated by odds ratio with 95% confidence interval. The independent effect of the 
explanatory variables was evaluated by a multiple logistic regression model which included 
all explanatory variables that obtained p < 0.20 in the Wald test in simple regression. The 
goodness of fit of the multiple model was verified by the area under the Receiver Operating 
Characteristic curve (above 0.7). The level of significance was 5% for all analyses, performed 
using R software version 3.4.0.
Siclom: Sistema de Controle Logístico de Medicamentos (Logistic Control System of Medicines); Sinan: Sistema de 
Informação de Agravos de Notificação (Information System for Notifiable Diseases); ART: Antiretroviral therapy
Figure. Diagram of patients’ inclusion in the cohort. Belo Horizonte, State of Minas Gerais, 2015.
Exclusion criteria (n = 809)
• Previous use of ART (n = 390)
• Follow-up in other healthcare 
service (n = 172)
• Transference to other healthcare 
service after discharge from hospital 
(n = 110)
• Death with follow-up in other 
healthcare service (n = 107)
• No outpatient follow-up after 
discharge from hospital (n = 16)
• No initial ART (n = 8)
• Follow-up during pregnancy (n = 3)
• No confirmed HIV diagnosis (n = 3)
Patients registered at Siclon 
between January 2014 and 
December 2015 n = 557
Duplicate patients
n = 456
Distinct patients
n = 1,249
Patients included
n = 440
Patients notified at Sinan 
between January 2014 and 
December 2015 n = 1,148
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Three scenarios were constructed to evaluate the impact of missing data on the analysis 
outcomes: in the first, only patients with observed data were evaluated; in the second, 
missing data were considered as success (VL < 50 copies/ml), and, in the third, missing 
data were considered as failure (VL ≥ 50 copies/ml).
The missing data were replaced using multiple imputation by chained equations (MICE 
package, m = 20)6. The percentage of missing data was up to 30% for explanatory variables, 
and 23.8% at six months and 22.7% at 12 months for effectiveness. Imputation consistency 
was assessed by Pearson correlation between the predicted values of the estimated model 
using only observed data and data of the imputed model (R2 = 0.99 for six months and 
R2 = 0.83 for 12 months). No differential loss was observed between the groups that reached 
viral suppression or not according to the explanatory variables.
This study is part of the ECOART project “Efetividade da terapia antirretroviral em 
pessoas vivendo com HIV, HIV/tuberculose, HIV/hanseníase ou HIV/leishmaniose visceral, 
acompanhados em Belo Horizonte” (Effectiveness of antiretroviral therapy in people living 
with HIV, HIV/tuberculosis, HIV/leprosy or HIV/visceral leishmaniasis, followed up in Belo 
Horizonte) approved by the Research Ethics Committee of Universidade Federal de Minas 
Gerais (CAAE 31192014.3.0000.5149; 2014) and Hospital Eduardo de Menezes (877,392).
RESULTS
The median follow-up time was 11 months; 22.0% of patients were hospitalized and 11 died 
over this period. Most patients were male (74.3%) and the main category of risk or exposure 
to HIV infection was MSM (32.3%), followed by heterosexual men (30.0%). Many patients 
entered the cohort with advanced immunosuppression, characterized by CD4 + counts 
below 200 cells/mm3 (32.0%) and presence of AIDS-defining signs and symptoms (45.7%), 
although most had no record of hospitalization due to HIV in the year prior to entering the 
cohort (52.7%) (Table 1).
During follow-up, 60.7% of patients recorded infectious and parasitic diseases, of whom 
28.9% presented HIV complications and 18.2% infections with a predominantly sexual mode 
of transmission. Co-infection by tuberculosis and hepatitis B or C occurred in 10.0% and 
2.3% of the population, respectively. In addition, 25.9% of patients had a record of mental 
or behavioral disorder, the most common being depression (n = 67, 15.2%) and anxiety 
(n = 22, 5.0%).
The ART was mainly initiated at outpatient level (63.6%) with regimens that combined 
two nucleoside/nucleotide reverse transcriptase inhibitors (NRTI) associated with a 
non-nucleoside reverse transcriptase inhibitor (NNRTI) (92.0%) – mainly efavirenz (90.7%). 
The most common drug combination was tenofovir, lamivudine and efavirenz (85.0%), 
followed by zidovudine, lamivudine and efavirenz (3.6%). The interval between diagnosis 
and initial ART was up to 60 days for approximately half of patients (52.5%), with an average 
of 1.1 years (SD = 2.7; TA = 21). Adherence to treatment was higher in the first six months, 
83.4% of patients, versus 73.4% at 12 months. At least one incident ART-related adverse 
reaction was recorded for 50.9% of patients and ARV switch for 23.9%. The use of illicit 
drugs and tobacco reduced after initial ART (Table 1).
The distribution of patients in the STR and MTR groups was mostly similar regarding 
sociodemographic, clinical, ART-related and behavioral and lifestyle characteristics. 
However, compared to the MTR group, patients who used STR had a higher level of 
education, fewer were browns, had a lower prevalence of mental disorders, more recent 
HIV diagnosis, and lower incidence of adverse reactions to ART and ARV switch (p < 0.05) 
(Table 1).
Viral suppression was observed for 74.6% of patients at six months of follow-up, and this 
percentage was higher among patients in the STR group (p = 0.035). Viral suppression 
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Table 1. Characteristics of patients included in the study. Belo Horizonte, State of Minas Gerais, 2015. (n = 440) 
Variable 
Total (n = 440) STR (n = 185) MTR (n = 255)
n % n % n %
Sociodemographic
Sex
Female 113 25.7 43 23.2 70 27.5
Male 327 74.3 142 76.8 185 72.5
Age (years)
16 to 36 218 49.5 91 49.2 127 49.8
> 36 to 77 222 50.5 94 50.8 128 50.2
Level of education
Secondary or higher education 194 44.1 97 52.4a 97 38.0
Illiterate to complete primary education 175 39.8 65 35.1 110 43.1
Missing data 71 16.1 23 12.4 48 18.8
Race/skin color
Non-brown 163 37.0 84 45.4a 79 31.0
Brown 272 61.8 99 53.5 173 67.8
Missing data 5 1.1 2 1.1 3 1.2
Marital status
Married/Stable union 128 29.1 54 29.2 74 29.0
Divorced/Single/Widowed 310 70.5 130 70.3 180 70.6
Missing data 2 0.5 1 0.5 1 0.4
Employment 
Yes 224 50.9 90 48.6 134 52.5
No 182 41.4 76 41.1 106 41.6
Missing data 34 7.7 19 10.3 15 5.9
Children
Yes 204 46.4 86 46.5 118 46.3
No 190 43.2 76 41.1 114 44.7
Missing data 46 10.5 23 12.4 23 9.0
Clinical/Laboratory
Risk/Exposure category
Heterosexual female 100 22.7 36 19.5 64 25.1
Heterosexual male 132 30.0 56 30.3 76 29.8
MSM 142 32.3 57 30.8 85 33.3
Injecting drugs/Other 13 3.0 6 3.2 7 2.7
Missing data 53 12.0 30 16.2 23 9.0
Viral load before ART
Up to 100,000 copies/ml 179 40.7 88 47.6 91 35.7
> 100,000 copies/ml 129 29.3 51 27.6 78 30.6
Missing data 132 30.0 46 24.9 86 33.7
CD4+ before ART
> 500 cells/mm3 77 17.5 33 17.8 44 17.3
201 to 499 cells/mm3 98 22.3 37 20.0 61 23.9
Up to 200 cells/mm3 141 32.0 65 35.1 76 29.8
Missing data 124 28.2 50 27.0 74 29.0
Medical conditionc
With AIDS (C) 201 45.7 82 44.3 119 46.7
Without AIDS (A/B) 239 54.3 103 55.7 136 53.3
Hospitalizations in previous year
0 232 52.7 104 56.2 128 50.2
1 156 35.5 56 30.3 100 39.2
2 or more 52 11.8 25 13.5 27 10.6
Hospitalizations during follow-up
0 343 78 147 79.5 196 76.9
1 77 17.5 29 15.7 48 18.8
2 or more 20 4.5 9 4.9 11 4.3
Hepatitis B or C during follow-up
Yes 10 2.3 6 3.2 4 1.6
No 430 97.7 179 96.8 251 98.4
Mental disorder during follow-up
Yes 114 25.9 34 18.4a 80 31.4
No 326 74.1 151 81.6 175 68.6
Continue
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ART-related
Initial treatment 
Outpatient unit 280 63.6 126 68.1 154 60.4
Hospital 160 36.4 59 31.9 101 39.6
Year 
2014 210 47.7 - - 210 82.4
2015 230 52.3 185 100 45 17.6
Initial ART regimen (2 NRTI)
INI 1 0.2 - - 1 0.4
PI 34 7.7 - - 34 13.3
NNRTI 405 92 185 100 220 86.3
Time between diagnosis and ART
Up to 2 months 231 52.5 108 58.4a 123 48.2
> 2 months 209 47.5 77 41.6 132 51.8
Record of AR to ART during follow-up
Yes 224 50.9 65 35.1a 159 62.4
No 216 49.1 120 64.9 96 37.6
ARV switchb during follow-up
Yes 105 23.9 28 15.1a 77 30.2
No 335 76.1 157 84.9 178 69.8
Record of adherence to ART in 6 months
Yes 367 83.4 158 85.4 209 82
No 73 16.6 27 14.6 46 18
Record of adherence to ART in 12 months
Yes 323 73.4 140 75.7 183 71.8
No 117 26.6 45 24.3 72 28.2
Behavioral and lifestyle
Previous tobacco use
Yes 223 50.7 98 53.0 125 49.0
No 132 30.0 61 33.0 71 27.8
Missing data 85 19.3 26 14.1 59 23.1
Previous alcohol use
Yes 288 65.5 136 73.5 152 59.6
No 67 15.2 28 15.1 39 15.3
Missing data 85 19.3 21 11.4 64 25.1
Previous illicit drugs use
Yes 142 32.3 76 41.1 66 25.9
No 179 40.7 82 44.3 97 38.0
Missing data 119 27.0 27 14.6 92 36.1
Tobacco use during follow-up
Yes 148 33.6 59 31.9 89 34.9
No 264 60.0 114 61.6 150 58.8
Missing data 28 6.4 12 6.5 16 6.3
Alcohol use during follow-up
Yes 202 45.9 90 48.6 112 43.9
No 204 46.4 81 43.8 123 48.2
Missing data 34 7.7 14 7.6 20 7.8
Illicit drugs use during follow-up
Yes 71 16.1 35 18.9 36 14.1
No 302 68.6 123 66.5 179 70.2
Missing data 67 15.2 27 14.6 40 15.7
STR: single-tablet regimen; CD4+: CD4+T lymphocites; MSM: men who have sex with men; MTR: multiple-tablet 
regimen; INI: integrase inhibitors; PI: protease inhibitors; NRTI: nucleoside/nucleotide reverse transcriptase 
inhibitors; NNRTI: non-nucleoside reverse transcriptase inhibitor; AR: adverse reaction; ARV: antiretroviral drug; 
ART: antiretroviral therapy
a p < 0.05 in the chi-square test for observed data.
b Replacement of an initially prescribed active ingredient by another.
c Clinical classification according to adapted criteria of Centers for Disease Control and Prevention; 
A: asymptomatic, B: symptomatic, C: AIDS-defining symptoms.
Table 1. Characteristics of patients included in the study. Belo Horizonte, State of Minas Gerais, 2015. 
(n = 440). Continuation
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results in the other scenarios followed the same trend, although statistical significance 
was observed only in the success scenario (Table 2).
At 12 months of follow-up, 83.2% of the patients reached viral suppression, with no 
statistically significant difference between the STR and MTR groups (p = 0.929) in all 
proposed scenarios. In this period, 75.2% of patients reached immunological recovery, 
also without differences between the groups. However, the percentage of missing data 
for this outcome was high (53.2%), which may compromise the interpretation of results 
in the proposed scenarios (Table 2).
Bivariate analysis with imputed data showed different factors associated with 
viral suppression at six and 12 months. Sociodemographic characteristics did not 
inf luence the outcome, whereas clinical variables related to disease progression and 
immunosuppression at the baseline were associated with lower effectiveness: presence 
of AIDS-defining signs and symptoms and hospitalization records in the year prior to 
entry into the cohort and viral load above of 100,000 copies/ml for effectiveness at six 
and 12 months (p < 0.05) (Table 3).
Among ART-related characteristics, antiretroviral drug switch was negatively associated 
with effectiveness at six and 12 months, while adherence was positively associated 
with effectiveness in both periods (p < 0.05). At six months, initiating treatment during 
hospitalization and use of MTR were associated with a lower probability of achieving 
effectiveness (p < 0.05), while initiating therapy in 2015 and diagnostic time above two 
months increased the likelihood of achieving viral suppression (p < 0.05). The extent of 
viral suppression at six months was strongly associated with achieving effectiveness at 12 
months of treatment (OR = 7.78 and p < 0.001) (Table 3).
Tobacco use during follow-up was negatively associated with viral suppression, and illicit 
drug use during follow-up reduced the chance of achieving viral suppression at 12 months 
(p < 0.05) (Table 3).
Clinical, ART-related, behavioral and lifestyle factors remained in the final model 
associated with effectiveness in the multiple analysis with imputed data. Viral load above 
100,000 copies/ml (p = 0.017) and presence of AIDS-defining signs and symptoms (p = 
0.014) were associated with approximately 55.0% and 70.0% less likelihood of achieving 
viral suppression at six months, as were ARV switch (p < 0.001) and tobacco use during 
Table 2. Effectivity results according to follow-up time and evaluated scenario. Belo Horizonte, State 
of Minas Gerais, 2015. (n = 440)
Effectiveness rate
Overall (n = 440) STR (n = 185) MTR (n = 255)
n % n % n %
6 months
Viral load
Observed data 250/335 74.6 112/139 80.6* 138/196 70.4
Success scenario 355/440 80.7 158/185 85.4* 197/255 77.3
Failure scenario 250/440 56.8 112/185 60.5 138/255 54.1
12 months
Viral load
Observed data 283/340 83.2 116/139 83.5 167/201 83.1
Success scenario 383/440 87.0 162/185 87.6 221/255 86.7
Failure scenario 283/440 64.3 116/185 62.7 167/255 65.5
Immunological recovery
Observed data 155/206 75.2 54/67 80.6 101/139 72.7
Success scenario 389/440 88.4 172/185 93.0* 217/255 85.1
Failure scenario 155/440 35.2 54/185 29.2* 101/255 39.6
STR: single-tablet regimen; MTR: multiple-tablet regimen
* p < 0.05 in the chi-square test.
Observed data: patients who presented observed data; Success scenario: all missing data are considered success; 
Failure scenario: all missing data are considered failure.
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follow-up (p = 0.005). Only adherence to ART increased the chance of achieving viral 
suppression (OR = 2.11, p = 0.029) (Table 4).
The multiple model with imputed data showed that achieving viral suppression at six months 
was the main predictor of effectiveness at 12 months (OR = 8.96, p < 0.001). In addition, 
adherence to ART at 12 months and belonging to the MSM category increased the likelihood 
of achieving viral suppression (p < 0.05), while use of illicit drugs during follow-up reduced 
that likelihood by 66.0% (Table 4).
Table 3. Bivariate analysis of effectiveness evaluated by viral suppression according to follow-up time and patients’ characteristics. Belo 
Horizonte, State of Minas Gerais, 2015. (n = 440)
Variable
6 months 12 months
OR 95%CI p OR 95%CI p
Sociodemographic
Sex (male) 0.62 0.34–1.12 0.115 0.61 0.30–1.18 0.159
Age (> 36 years) 0.83 0.51–1.37 0.474 1.33 0.75–2.36 0.333
Level of education (up to complete primary) 0.78 0.48–1.27 0.314 0.97 0.56–1.67 0.900
Race/Skin color (brown) 0.62 0.38–1.02 0.060 1.10 0.60–2.00 0.763
Marital status (single, divorced, widowed) 1.03 0.62–1.71 0.912 1.26 0.69–2.31 0.451
Employment (no) 1.23 0.72–2.08 0.445 1.46 0.81–2.64 0.203
Children (yes) 0.88 0.53–1.47 0.626 0.71 0.40–1.27 0.245
Clinical
HIV Risk/Exposure (MSM versus heterosexuals, IDU, others) 1.00 0.58–1.72 0.992 1.59 0.80–3.16 0.183
Viral load before ART (> 100,000 copies/ml) 0.35 0.19–0.65 0.001 0.54 0.32–0.94 0.030
AIDSa (yes) 0.27 0.16–0.46 0.000 0.57 0.32–1.01 0.053
Hepatitis B or C (yes) 0.50 0.14–1.81 0.289 - - 0.999
Mental disorder (yes) 0.63 0.37–1.10 0.101 0.61 0.33–1.12 0.108
Hospitalization in previous year (yes) 0.45 0.27–0.75 0.002 0.87 0.49–1.53 0.625
Hospitalization during follow-up (yes) 0.72 0.40–1.27 0.255 1.01 0.49–2.07 0.981
ART-related
Initial treatment (hospital level) 0.40 0.24–0.66 0.000 0.91 0.50–1.64 0.749
Initial year of treatment (2015) 1.73 1.05–2.85 0.030 1.00 0.57–1.77 0.999
Initial ART regimen (PI versus NNRTI) 0.70 0.29–1.69 0.431 0.68 0.26–1.77 0.431
Initial ART regimen (MTR) 0.57 0.34–0.97 0.036 0.97 0.55–1.74 0.929
Time between diagnosis and ART (> 2 months) 1.70 1.02–2.84 0.043 0.68 0.39–1.21 0.189
Record of AR to ART (yes) 0.88 0.53–1.43 0.597 0.99 0.56–1.74 0.963
ARV switchb (yes) 0.24 0.14–0.42 0.000 0.52 0.28–0.95 0.035
Adherence to ART in 6 months (yes) 2.28 1.25–4.14 0.007 - - -
Adherence to ART in 12 months (yes) - - - 4.04 2.24–7.31 0.000
Effectiveness at 6 months (yes) - - - 7.78 3.83–15.78 0.000
Behavioral and lifestyle
Tobacco use in life (yes) 0.72 0.41–1.28 0.265 0.60 0.31–1.16 0.127
Alcohol use in life (yes) 0.86 0.46–1.28 0.631 0.76 0.35–1.67 0.487
Drug use in life (yes) 0.66 0.40–1.06 0.087 0.52 0.27–1.01 0.053
Recent tobacco use (sim) 0.49 0.31–0.78 0.003 0.43 0.23–0.80 0.009
Alcohol use during follow-up (yes) 1.00 0.58–1.71 0.991 0.75 0.41–1.36 0.335
Drug use during follow-up (yes) 0.66 0.34–1.28 0.222 0.39 0.21–0.73 0.004
CD4+: CD4+T lymphocites; MSM: men who have sex with men; IDU: injecting drug user; MTR: multiple-tablet regimen; PI: protease inhibitors; NNRTI: 
non-nucleoside reverse transcriptase inhibitor; AR: adverse reaction; ARV: antiretroviral drug; ART: antiretroviral therapy
a Clinical classification according to adapted criteria of Centers for Disease Control and Prevention.
b Replacement of an initially prescribed active ingredient by another.
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DISCUSSION
In this Brazilian cohort study, which included only ART-naïve patients, the overall 
effectiveness of antiretroviral therapy was high, 74.6% at six months and 83.2% at 12 
months of treatment, similar to rates in developed countries7,8. The single-tablet regimen 
with tenofovir, lamivudine and efavirenz was associated with greater viral suppression at 
six months of treatment compared to multiple-tablet regimens.
The characteristics of the patients included in this study are similar to the profile of PLHIV 
in Brazil, as published in epidemiological bulletins and other national studies3,4,a. Patients 
were predominantly male, sexually infected and heterosexual. Most patients initiated ART 
with two NRTI associated with one NNRTI, in accordance with the Clinical Protocol and 
Therapeutic Guidelines in force at the timec.
Overall effectiveness at six months agrees with the results obtained by Cardoso et al.4 in 
a cohort of patients in Rio de Janeiro (76.9%). At 12 months of follow-up, the result (83.2%) 
was slightly higher than those reported in Brazilian studies carried out between 2000 and 
2010 (76.1% and 77.4%)3,4, and higher than those observed in previous studies, 46.9% and 
48.4% between 1997 and 20049,10. This difference may reflect the shorter interval between 
diagnosis and initial therapy, according to changes in initial therapy7,c. In addition, the 
better performance of newer drugs and formulations, which reduce the occurrence of 
adverse events, provide greater dosage convenience, and require a lower adherence rate to 
be effective may have contributed to this difference4,11.
The simplified therapy regimen with daily ingestion of tablets only once a day is associated 
with the higher level of adherence of patients to ART and higher levels of viral suppression 
when using STR or absence of difference between groups2. In this cohort, effectiveness results 
for patients using STR were similar to results published in randomized controlled trials 
in ART-naïve patients, which reported viral suppression rates between 80% and 88%12–14, 
albeit with different regimen compositions.
These results reinforce the strategy of supplying generic drugs in STR in Brazil. Although 
the difference between groups was not statistically significant at 12 months of follow-up, 
there was a trend of better results for patients using this drug regarding the incidence of 
adverse events, switch of therapy regimens, adherence to treatment and immunological 
recovery, as well as higher viral suppression at six months of ART.
Table 4. Multivariate analysis of effectiveness evaluated by viral suppression according to follow-up time and patients’ characteristics. Belo 
Horizonte, State of Minas Gerais, 2015. (n = 440)
Variable
6 monthsa,b 12 monthsc,d
OR 95%CI p OR 95%CI P
Clinical
HIV risk (MSM versus other groups) - - - 2.44 1.04–5.69 0.040
Viral load before ART (> 100,000 copies/ml) 0.40 0.19–0.84 0.017 - - -
AIDS (yes) 0.47 0.26–0.86 0.014 - - -
ART-related
Time between diagnosis and ART (> 2 months) - - - 0.40 0.19–0.84 0.017
ARV switche (yes) 0.31 0.17–0.56 0.000 - - -
Adherence to ART in 6 months (yes) 2.11 1.08–4.13 0.029 - - -
Adherence to ART in 12 months (yes) - - - 2.34 1.14–4.79 0.020
Effectiveness at 6 months (yes) - - - 8.96 3.98–20.17 0.000
Behavioral
Recent tobacco use (yes) 0.45 0.26–0.79 0.005 - - -
Drug use during follow-up (yes) - - - 0.34 0.15–0.79 0.012
ARV: antiretroviral drug; MSM: men who have sex with men; ART: antiretroviral therapy; ROC: Receiver Operating Characteristic
a Area under ROC curve = 0.785. 
b Pearson coeficiente correlation R2 = 0.99.
c Area under ROC curve = 0.974. 
d Pearson coeficiente correlation R2 = 0.83.
e Replacement of an initially prescribed active ingredient by another.
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The effectiveness of antiretroviral therapy was influenced by clinical, behavioral and ART-related 
factors. Among the factors that predicted effectiveness at six months, initiating treatment 
with high viral load and AIDS-defining signs and symptoms were negatively associated with 
viral suppression, as reported in previous studies8,15–17. Initiating ART regardless of CD4+ cell 
counts has been adopted in Brazil since 2013. Recent studies indicate a 50% reduction in the 
incidence of serious AIDS-related events, such as death and opportunistic diseases, among 
patients who initiate ART early (CD4+ count > 500 cells/mm3)18,19. Patients who initiated ART 
within a shorter interval after diagnosis had a greater chance of achieving viral suppression at 
12 months in this study.
Despite knowledge of these benefits and policies introduced to increase access to diagnosis 
and treatment, such as expansion of testing sites and availability of quick diagnostic testsh, 
most patients initiated ART with advanced immunosuppression. The same pattern was 
observed in Brazilian studies in previous years3,20 and may be related to difficult access to 
healthcare services and lack of knowledge and awareness of the population about HIV risks. 
This results in late search for healthcare services and, consequently, late initiation of ART20.
The MSM were more likely to achieve viral suppression after 12 months of treatment 
compared to other risk or exposure categories. This result may reflect a greater involvement 
of those patients in continuous healthcare21. However, further studies are needed for 
inferences in this population.
The ARV switch and ART adherence influenced viral suppression. The ARV switch is 
associated with lower adherence to treatment and may be more closely related to the 
occurrence of adverse events and intolerance rather than virologic failure22,23. It may also 
be due to timely monitoring of effectiveness.
The relationship between adherence to treatment and ART effectiveness is well documented 
in the literature8,10,16 and the lowest level of adherence required to ensure the effectiveness of 
antiretroviral drugs is between 80.0% and 95.0%11. In this study, non-adherence was observed 
in the medical records of 16.6% of patients over six months and 26.6% over 12 months. Such 
data are worrying, since medical records underestimate actual non-adherence figures. 
Non-adherence may lead to the development of viral resistance, progression of the disease, 
increased morbidity and mortality due to AIDS and contribute to increase patient care costs10,11.
Viral suppression at six months was the main predictor of effectiveness in one year16,17. No 
patients in this study had previously used ART. Considering the prevalence of HIV-resistant 
strains in Brazil (11.6%)24, failure of viral suppression is probably due to non-adherence, 
although resistance to NNRTI antiretroviral drugs has increased in Minas Gerais25. Checking 
patients’ adherence to therapy and carrying out actions to increase it are as important as 
timely monitoring of viral load and performance of genotyping tests to ensure adequate 
response to treatment.
Use of substances such as tobacco and illicit drugs during follow-up were associated 
with lower likelihood of achieving viral suppression. Tobacco use among PLHIV has been 
linked to worse clinical outcomes, such as increased viral load, reduced CD4+ cell count 
and increased occurrence of opportunistic infections26,27. The negative impact of tobacco 
use and its high prevalence in this population evidence the need to enhance non-smoking 
programs in HIV/AIDS specialized units.
The use of illicit substances among PLHIV may be related both to the actual source of infection 
and to diagnosis coping mechanisms28. The use of these substances is related to lower levels of 
adherence to treatment, lower viral suppression and lower levels of CD4+28,29. Worse results are 
also reported with previous use of illicit drugs3,29,30. Treating chemical dependency, introducing 
other methods to help cope with the diagnosis and raising the health team’s awareness of the 
problem28–30 are possible strategies to improve the clinical results of these patients.
h Ministério da Saúde (BR), 
Secretaria de Vigilância em Saúde, 
Departamento de Vigilância, 
Prevenção e Controle das IST, do 
HIV/AIDS e das Hepatites Virais. 
Relatório de monitoramento 
clínico do HIV - 2016. Brasília 
(DF); 2016 [cited 2017 Apr 20]. 
Available from: http://www.aids.
gov.br/pt-br/pub/2016/relatorio-
de-monitoramento-clinico-do-
hiv-2016
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This study has limitations, such as poor accuracy of measurements collected from medical 
records and high percentage of missing data. The strategies used to minimize their effect 
were the elaboration of clinical scenarios and data imputation, with no change in the trend 
of results. Study strengths include the high quality of collection, the broad inclusion of 
confounding factors, and the robustness of the final model in both follow-up periods
The incidence of viral suppression at six and 12 months in patients with no prior use of 
ART was high, with differences between patients using STR and MTR. Clinical, behavioral, 
lifestyle, and ART-related factors influenced viral suppression. They also demonstrated the 
need for interventions to improve diagnosis and the timely initiation of treatment, patients’ 
adherence to therapy, and the reduction of tobacco and illicit drugs use, so as to optimize 
treatment outcome and contribute to quality of life and reduction of HIV transmission.
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